Drug Approval

Showing 358 articles
Business

Ethereum's 2026: The Year of Convergence?

After a period of Bitcoin dominance, a confluence of technological maturity, shifting institutional narratives, and regulatory clarity could propel Ethereum back into the spotlight. Analysts point to its foundational role in decentralized finance and a series of upcoming catalysts as reasons for a potential breakout year.

Business

Robinhood's Triple Play: From Trump Accounts to SpaceX IPO and Tokenization

Robinhood is positioning itself at the center of three major financial shifts: potentially administering new federal savings accounts, vying for a key role in SpaceX's blockbuster IPO, and expanding into tokenized assets. This strategic pivot could redefine the fintech's role from a trading app to a core financial infrastructure player.

Business

Galenica's Five-Year Surge: A 90% Return for Patient Investors

Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.